Certainly, Madam Chair.
In our experience at the National Microbiology Lab we have developed a number of candidate vaccines for viral hemorrhagic fevers. We have in fact had no problem identifying manufacturing capacity for trial lots. There are many U.S. and European companies and a couple of Canadian ones that have that ability. I know of a company, Microbix, in Ontario that offers this capability. McMaster University has developed a good manufacturing practice facility for manufacturing trial lots of vaccines. And I've had companies come to me asking if I had anything for them to manufacture.
So I have no reason to disbelieve the Gates study, and I believe that there is a lot of capacity for manufacturing trial lots up there—that is, in small contract research organizations.